A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Regenxbio Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 68,000 shares of RGNX stock, worth $518,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,000
Previous 75,900 10.41%
Holding current value
$518,160
Previous $888,000 19.71%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.49 - $14.39 $82,871 - $113,681
-7,900 Reduced 10.41%
68,000 $713,000
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $215,237 - $402,611
18,700 Added 32.69%
75,900 $888,000
Q1 2024

May 15, 2024

BUY
$12.17 - $24.61 $542,782 - $1.1 Million
44,600 Added 353.97%
57,200 $1.21 Million
Q4 2023

Feb 14, 2024

BUY
$12.89 - $20.82 $162,414 - $262,332
12,600 New
12,600 $226,000
Q1 2023

May 15, 2023

SELL
$18.08 - $24.55 $45,199 - $61,375
-2,500 Reduced 19.08%
10,600 $200,000
Q4 2022

Feb 14, 2023

SELL
$20.4 - $24.73 $169,320 - $205,259
-8,300 Reduced 38.79%
13,100 $297,000
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $91,389 - $143,664
4,100 Added 23.7%
21,400 $566,000
Q2 2022

Aug 15, 2022

BUY
$19.35 - $35.04 $79,335 - $143,664
4,100 Added 31.06%
17,300 $427,000
Q1 2022

May 16, 2022

BUY
$24.62 - $34.31 $324,984 - $452,892
13,200 New
13,200 $438,000
Q4 2021

Feb 14, 2022

SELL
$30.19 - $40.28 $1.6 Million - $2.13 Million
-53,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $1.18 Million - $1.86 Million
40,700 Added 330.89%
53,000 $2.22 Million
Q2 2021

Aug 16, 2021

SELL
$32.46 - $40.48 $892,650 - $1.11 Million
-27,500 Reduced 69.1%
12,300 $478,000
Q1 2021

May 17, 2021

BUY
$33.61 - $49.95 $1.34 Million - $1.99 Million
39,800 New
39,800 $1.36 Million
Q3 2019

Nov 14, 2019

SELL
$31.84 - $50.88 $1.14 Million - $1.83 Million
-35,900 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$42.0 - $59.29 $2.26 Million - $3.19 Million
-53,800 Reduced 59.98%
35,900 $1.84 Million
Q1 2019

May 15, 2019

SELL
$40.82 - $62.45 $1.91 Million - $2.92 Million
-46,800 Reduced 34.29%
89,700 $5.14 Million
Q4 2018

Feb 14, 2019

BUY
$39.11 - $75.15 $109,508 - $210,420
2,800 Added 2.09%
136,500 $5.73 Million
Q3 2018

Nov 14, 2018

BUY
$65.0 - $82.15 $8.03 Million - $10.2 Million
123,600 Added 1223.76%
133,700 $10.1 Million
Q2 2018

Aug 14, 2018

SELL
$27.2 - $74.35 $228,480 - $624,540
-8,400 Reduced 45.41%
10,100 $725,000
Q1 2018

May 15, 2018

SELL
$24.05 - $37.5 $86,002 - $134,100
-3,576 Reduced 16.2%
18,500 $552,000
Q4 2017

Feb 14, 2018

BUY
$26.0 - $34.6 $573,976 - $763,829
22,076
22,076 $734,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.